Why the study?
Distinguishing well-differentiated from dedifferentiated liposarcoma is essential for treatment planning, but percutaneous biopsy has low sensitivity for detecting dedifferentiation.
Does PET/CT imaging distinguish well-differentiated from dedifferentiated liposarcoma in patients with recurrent liposarcoma?
Does PET/CT imaging distinguish well-differentiated from dedifferentiated liposarcoma in patients with recurrent liposarcoma?
PET/CT imaging using a SUVmax cutoff of 4 provides high sensitivity and specificity for distinguishing dedifferentiated from well-differentiated liposarcoma.
Answers are grounded in this paper and cite their sources.
May support PET/CT differentiation of DDLPS in recurrent liposarcoma; hypothesis-generating and requires prospective validation before clinical use.
Distinguishing well-differentiated liposarcoma (WDLPS) from dedifferentiated liposarcoma (DDLPS) is essential given distinct treatment paradigms and chemosensitivity. Percutaneous biopsy has a low sensitivity for detecting DDLPS. We sought to identify the diagnostic utility of positron emission tomography/computed tomography (PET/CT) in identifying WDLPS versus DDLPS. An independent radiologist reviewed PET/CT images to identify target lesions and determine the maximum standardized uptake value (SUVmax). An independent pathologist review confirmed WDLPS or DDLPS histology. A binary cutoff point of SUVmax was identified using a classification and regression trees (CART) algorithm. We identified 20 patients with WDLPS or DDLPS with 26 PET/CTs performed for separate recurrences that were followed by surgical sampling. Of the 26 records, 12 were DDLPS (46%) and 14 were WDLPS (54%). Patients with DDLPS had significantly higher SUVmax than those with WDLPS (pvalue = 0.0035). A SUVmax of 4 was identified as the cutoff point. Using this cutoff, the sensitivity of SUVmax identifying a case as DDLPS was 83.3% (95% CI: 51.6%, 97.9%) and the specificity was 85.7% (95% CI: 57.2%, 98.2%). PET/CT is a sensitive and specific diagnostic tool to identify the presence of dedifferentiation within the tumor.
No takes yet. Share an insight, caveat, or question.
Parkes et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: